Current report no.: 10/2023
Date of preparation: April 3, 2023.
Legal basis: Article 17 par. 1 of the MAR Regulation – confidential information.
The Management Board of Medicalgorithmics S.A. headquartered in Warsaw (“Company”) announces that its wholly-owned subsidiary, Kardiolytics Inc. (“Kardiolytics”), has been granted USA Patent No. 11626211. The Company has received notification from the United States Patent and Trademark Office on April 3, 2023, and the patent is expected to be published on or around April 11, 2023.
The patent concerns an autonomous method for modelling blood vessels and blood flow using a CT angiography scan. The method involves generating a three-dimensional personalized model of the blood vessels and a three-dimensional reference model of healthy blood vessels that lack lesions. The personalized model is then subjected to a numerical simulation of blood flow under the same physical and boundary conditions as the reference model. The simulation involves determining the conditions of blood flow at the inlet of the blood vessels model and calculating the energy of the blood flow for the inlet and all outlets of the model. The blood flow energy measured for the personalized model and the reference model are compared to determine flow energy change indexes. This method can be used to assess the impact of lesions or other abnormalities on blood flow and could potentially be used to diagnose or monitor vascular diseases.
This is the next patent obtained by Kardiolytics. Securing patents for innovations and technologies will enable Kardiolytics to promote and commercialize inventions, including its VCAST technology. Also, what is of the greatest importance – it will help protect Kardiolytics’ unique intellectual property to enable further development of the solution and improve CAD diagnostics (Coronary Artery Disease – the most common heart disease in the US).
Kardiolytics, a company creating solutions for medicine based on artificial intelligence, joined the Medicalgorithmics capital group in November 2022.
The Issuer’s Management is publishing this information as it aligns with the plan outlined in current report no. 58/2022.